Folgen
Zeda Zhang
Titel
Zitiert von
Zitiert von
Jahr
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
P Mu, Z Zhang, M Benelli, WR Karthaus, E Hoover, CC Chen, ...
Science 355 (6320), 84-88, 2017
10032017
Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones
D Liang, Y Feng, F Zandkarimi, H Wang, Z Zhang, J Kim, Y Cai, W Gu, ...
Cell 186 (13), 2748-2764. e22, 2023
2712023
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
EJ Adams, WR Karthaus, E Hoover, D Liu, A Gruet, Z Zhang, H Cho, ...
Nature 571 (7765), 408-412, 2019
2382019
Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer
Z Zhang, WR Karthaus, YS Lee, VR Gao, C Wu, JW Russo, M Liu, ...
Cancer Cell 38 (2), 279-296. e9, 2020
2142020
Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation
Z Zhang, C Zhou, X Li, SD Barnes, S Deng, E Hoover, CC Chen, YS Lee, ...
Cancer cell 37 (4), 584-598. e11, 2020
1392020
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis
R Bose, WR Karthaus, J Armenia, W Abida, PJ Iaquinta, Z Zhang, ...
Nature 546 (7660), 671-675, 2017
862017
Macrophages promote anti-androgen resistance in prostate cancer bone disease
XF Li, C Selli, HL Zhou, J Cao, S Wu, RY Ma, Y Lu, CB Zhang, B Xun, ...
Journal of Experimental Medicine 220 (4), e20221007, 2023
412023
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
X Li, Y Wang, S Deng, G Zhu, C Wang, NA Johnson, Z Zhang, CR Tirado, ...
Cancer cell 41 (8), 1427-1449. e12, 2023
282023
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon
D Gao, Y Zhan, W Di, AR Moore, JJ Sher, Y Guan, S Wang, Z Zhang, ...
PLoS One 11 (8), e0161084, 2016
262016
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
N Mao, Z Zhang, YS Lee, D Choi, AA Rivera, D Li, C Lee, S Haywood, ...
Nature Communications 12 (1), 5053, 2021
222021
A SMAD4‐modulated gene profile predicts disease‐free survival in stage II and III colorectal cancer
BC Szeglin, C Wu, MR Marco, HS Park, Z Zhang, B Zhang, ...
Cancer Reports 5 (1), e1423, 2022
192022
Oncogenic ERG represses PI3K signaling through downregulation of IRS2
N Mao, D Gao, W Hu, S Gadal, H Hieronymus, S Wang, YS Lee, ...
Cancer research 80 (7), 1428-1437, 2020
142020
Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer
E Lee, Z Zhang, CC Chen, D Choi, ACA Rivera, E Linton, Y Ho, J Love, ...
bioRxiv, 2024.03. 18.585532, 2024
12024
Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers
N Mao, YS Lee, N Salsabeel, Z Zhang, D Li, H Kaur, X Chen, Q Chang, ...
Science Advances 11 (6), eadq3802, 2025
2025
ROLE OF TUMOR MICROENVIRONMENT DERIVED NRG1 IN ANDROGEN RESISTANCE: IMPLICATIONS FOR A NOVEL PROSTATE CANCER TREATMENT STRATEGY
B Shinder, N Mao, N Salsabeel, Z Zhang, CL Sawyers, BS Carver
Urologic Oncology: Seminars and Original Investigations 42, S86-S87, 2024
2024
Abstract NG06: CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity
Z Zhang, C Zhou, X Li, S Barnes, S Deng, E Hoover, CC Chen, YS Lee, ...
Cancer Research 80 (16_Supplement), NG06-NG06, 2020
2020
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–16